In Jazz Pharmaceuticals, Inc. v. Avadel Cns Pharmaceuticals, LLC, Appeal No. 24-2274, the Federal Circuit held that injunctions prohibiting the initiation of new clinical trials for paper NDA drugs before patent expiration...more
Reliably Determining Reasonable Royalty Rates from Lump Sum Licenses - In Ecofactor, Inc. V. Google LLC, Appeal No. 23-1101, The Federal Circuit held that license agreements containing a lump sum payment “based on” a royalty...more
7/2/2024
/ Alice/Mayo ,
Appeals ,
Damages ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Google ,
Labeling ,
License Agreements ,
Lump Sum Payments ,
Motion to Dismiss ,
Patent Infringement ,
Patents ,
Pharmaceutical Patents ,
Royalties ,
Sports Gambling
Obviousness Analysis Does Not Consider Unclaimed Limitations - In Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals Usa, Inc., Appeal No. 22-1258, the Federal Circuit held that district court erred by adding unclaimed...more
Federal Circuit Orders District Court to Consider Extrinsic Evidence in Claim Construction -
In Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., Appeal No. 22-1889, the Federal Circuit held that where a...more
12/5/2023
/ Article III ,
Claim Construction ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Mylan Pharmaceuticals ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Purdue Pharma ,
Standing
Objective Evidence in Determining Obviousness -
In Medtronic, Inc. v. Teleflex Innovations, Appeal No. 21-2357, the Federal Circuit held that a close prima facie case of obviousness can be overcome by strong evidence of...more
7/20/2023
/ Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Medical Devices ,
Medtronic ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prior Art
避而不谈可能支持否定性权利要求限定 -
在 Novartis Pharmaceuticals 诉 Accord Healthcare Inc. 一案（上诉案件编号：21- 1070）中，联邦巡回上诉法院认为，一项对药物“速效剂量”避而不谈的专利申请，为要求不存在此类剂量的否定 性权利要求限制提供了书面说明支持。
...more
2/10/2022
/ Claim Construction ,
Indefiniteness ,
Intellectual Property Protection ,
Novartis ,
Patent Applications ,
Patent Examinations ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
記述がないことがクレームの否定的限定のサポートと解釈できる場合がある
Federal Circuit は、Novartis Pharmaceuticals v. Accord Healthcare Inc. (Appeal No. 21-1070) に おいて、薬剤の「初回負荷用量」についての記述がない特許出願は、そのような用量がないことを要 求するクレームの否定的限定に記述によるサポートを提供していることになると判示した。
...more
2/10/2022
/ Claim Construction ,
Indefiniteness ,
Intellectual Property Protection ,
Novartis ,
Patent Applications ,
Patent Examinations ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
January 2022 Federal Circuit Newsletter (Japanese) January 2022 Federal Circuit Newsletter (Chinese) Silence May Support Negative Claim Limitation In Novartis Pharmaceuticals v. Accord Healthcare Inc. Appeal No. 21-1070, the...more
2/9/2022
/ Claim Construction ,
Indefiniteness ,
Intellectual Property Protection ,
Novartis ,
Patent Applications ,
Patent Examinations ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
Ranges for Interdependent and Interactive Components Can Be Tricky to Derive -
In Modernatx, Inc. v. Arbutus Biopharma Corporation, Appeal No. 20-2329, the Federal Circuit held that a presumption of obviousness based on...more
1/11/2022
/ AstraZeneca ,
Generic Drugs ,
Instrinsic Evidence ,
Intel ,
Inter Partes Review (IPR) Proceeding ,
Moderna Inc. ,
Mylan Pharmaceuticals ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Prior Art ,
Qualcomm
Venue and Pleading Infringement in Hatch-Waxman Litigation Turn on Location and Identity of ANDA Filer -
In Celgene Corp. v. Mylan Pharm. et al., Appeal No. 21-1154, the Federal Circuit held that in Hatch-Waxman...more
12/9/2021
/ Abbreviated New Drug Application (ANDA) ,
Apple ,
Article III ,
Biogen Idec ,
Dr. Reddy’s Labs. ,
Generic Drugs ,
Hatch-Waxman ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Mylan Pharmaceuticals ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Qualcomm ,
Standing ,
Written Descriptions
Arguments to the Patent Office That Contradict Information Submitted to the FDA Support an Inference of Deceptive Intent
In Belcher Pharmaceuticals v. Hospira, Inc., Appeal No. 20-1799, the Federal Circuit held that a...more
10/6/2021
/ Deceptive Intent ,
Evidence ,
Failure To Disclose ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Hatch-Waxman ,
Hospira ,
Inequitable Conduct ,
Intellectual Property Protection ,
Motion to Transfer ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patent Prosecution ,
Patents ,
Pharmaceutical Patents ,
Post-Grant Review ,
Prior Art ,
USPTO ,
Venue
It’s No Secret That a Related Company’s Physical Presence in a Jurisdiction May Not Be Enough For Proper Venue -
In Andra Group, LP v. Victoria’s Secret Stores, LLC, Appeal No. 20-2009, The Federal Circuit held that an...more
9/20/2021
/ Abstract Ideas ,
Eli Lilly ,
Improper Venue ,
Inter Partes Review (IPR) Proceeding ,
Jurisdiction ,
Nexus ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Physical Presence Test ,
Preamble ,
Principal Place of Business ,
Retailers ,
Teva Pharmaceuticals ,
Victoria Secret
Specification’s Narrow Description of the Invention Results in Disavowal of Claim Scope -
In Techtronic Industries Co. Ltd. v. ITC., Appeal No. 18-2191, the consistent description in the specification of a particular...more
1/27/2020
/ Administrative Law Judge (ALJ) ,
Exceptional Case ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
International Trade Commission (ITC) ,
New Evidence ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Prior Art
The PTAB Cannot Approve or Deny Certificates of Correction -
In Honeywell International, Inc. v. Arkema Inc., Arkema France, Appeal Nos. 2018-1151, -1153, the Patent Trial and Appeal Board (“Board”) does not have the...more
11/25/2019
/ Abbreviated New Drug Application (ANDA) ,
Abuse of Discretion ,
Appeals ,
Certificate of Correction ,
Claim Construction ,
CLS Bank v Alice Corp ,
Cross Motions ,
Enablement Inquiries ,
Indefiniteness ,
Induced Infringement ,
JMOL ,
Judgment As A Matter Of Law ,
Leave to Amend ,
Mayo v. Prometheus ,
Motion for Summary Judgment ,
Nonobvious ,
Partial Reversal ,
Patent Applications ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Owner Preliminary Response ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Post-Grant Review ,
Priority Patent Claims ,
Product of Nature Doctrine ,
Reaffirmation ,
Remand ,
Scope of the Claim ,
Section 101 ,
Section 112 ,
Vacated ,
Written Descriptions
Mere Potential for Future Appeal Does Not Prevent Triggering Estoppel of Inter Partes Reexamination When Party Fails to Seek Relief in the First Instance -
In Virnetx Inc. v. Apple Inc., Appeal Nos. 2017-1591, -1592,...more
10/3/2019
/ Administrative Law Judge (ALJ) ,
Appeals ,
Claim Construction ,
Equivalency Determinations ,
Estoppel ,
Foreign Entities ,
Foreign Sovereigns ,
Indefiniteness ,
Inter Partes Reexamination ,
International Litigation ,
International Trade Commission (ITC) ,
IP License ,
Judgment As A Matter Of Law ,
Nonobvious ,
Novelty ,
Parallel Proceedings ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Personal Jurisdiction ,
Pharmaceutical Patents ,
Preliminary Injunctions ,
Reaffirmation ,
Remand ,
Section 101 ,
Subject Matter Jurisdiction ,
Universities ,
Vacated ,
Written Descriptions
Federal Circuit Determines Time-Barred Petitioner Joined to an IPR Has Appellate Standing -
In Mylan Pharmaceuticals Inc. v. Research Corporation Tech., Appeal Nos. 2017-2088, -2089, -2091, the Federal Circuit held that a...more
4/11/2019
/ § 315(b) ,
Affirmative Defenses ,
Appeals ,
Counterclaims ,
Defense Strategies ,
Denial of Rehearing ,
Diagnostic Method ,
Dismissals ,
En Banc Review ,
Google ,
Inter Partes Review (IPR) Proceeding ,
Joinder ,
Mandamus Petitions ,
Patent Infringement ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Principal Place of Business ,
Product of Nature Doctrine ,
Reaffirmation ,
Rebuttal ,
Remand ,
Right To Appeal ,
Section 101 ,
Software Patents ,
Sovereign Immunity ,
Standing ,
States Rights ,
Time-Barred Claims ,
Universities ,
Venue ,
Waivers
PTAB May Invalidate Claims on Reconsideration Based on Grounds Raised in the Institution Decision that Were Not Originally Instituted -
In AC Technologies S.A., V. Amazon.Com, Inc., Blizzard Entertainment, Inc., Appeal No....more
3/14/2019
/ Abbreviated New Drug Application (ANDA) ,
Amazon ,
Anticipation ,
Appeals ,
Article III ,
Due Process ,
Final Written Decisions ,
Generic Drugs ,
Hatch-Waxman ,
Hewlett-Packard ,
Inter Partes Review (IPR) Proceeding ,
Motivation to Combine ,
Mylan Pharmaceuticals ,
Obviousness ,
Orange Book ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Petition For Rehearing ,
Pharmaceutical Patents ,
Reaffirmation ,
Right To Appeal ,
Section 103 ,
Standing
A Post-URAA Patent that Issues After but Expires Before a Related Pre-URAA Patent Is Not a Double-Patenting Reference Against the Pre-URAA Patent -
In Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical Inc.,...more
2/8/2019
/ Abbreviated New Drug Application (ANDA) ,
Abstract Ideas ,
Appeals ,
Declaratory Judgments ,
Dismissals ,
Dispute Letters ,
Double Patent ,
Due Process ,
Improper Venue ,
Long Arm Statute ,
Minimum Contacts ,
Obviousness-Type Double Patenting (ODP) ,
Patent Expiration ,
Patent Infringement ,
Patent Invalidity ,
Patent Term Extensions ,
Patent Terms ,
Patent Validity ,
Patents ,
Personal Jurisdiction ,
Pharmaceutical Patents ,
Reaffirmation ,
Reversal ,
Stipulated Judgment ,
Uruguay Round Agreements Act (URAA)
Federal Circuit Finds Claims Directed to Tabbed Spreadsheets Patent Eligible and Claims Directed to Tracking Changes in Documents Ineligible Under Section 101 -
In Data Engine Technologies LLC v. Google LLC, Appeal No....more
12/7/2018
/ Abstract Ideas ,
Appeals ,
CLS Bank v Alice Corp ,
Hatch-Waxman ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Mayo v. Prometheus ,
Mylan Pharmaceuticals ,
Patent Invalidity ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
POSITA ,
Prior Art ,
Product of Nature Doctrine ,
Reaffirmation ,
Remand ,
Reversal ,
Sandoz ,
Section 101 ,
Summary Judgment ,
Teva Pharmaceuticals
Knobbe Martens Partners Paul Conover, Irfan Lateef, and Curtis Huffmire presented "Patent Law Update for Medical Device Companies 2018" at the MedTech Innovation Summit in San Francisco, CA on November 28, 2018. This session...more
12/5/2018
/ Abstract Ideas ,
Administrative Procedure ,
America Invents Act ,
Biotechnology ,
Claim Amendments ,
Constitutional Challenges ,
Copyright ,
Health IT ,
Innovative Technology ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Medical Devices ,
Oil States Energy Services v Greene's Energy Group ,
Patent Invalidity ,
Patent Portfolios ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Presidential Nominations ,
Private Property ,
Product of Nature Doctrine ,
SCOTUS ,
Trade Secrets ,
Trademarks ,
Trump Administration
Priority Claims Cannot Be Incorporated by Reference -
In Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited, Appeal Nos. 2016-2707 and 2016-2708, the Federal Circuit held that when a patent for a...more
6/25/2018
/ Abbreviated New Drug Application (ANDA) ,
Abuse of Discretion ,
Appeals ,
Claim Construction ,
Clear Error Standard ,
Consolidated Appeals ,
Diagnostic Method ,
Disclaimers ,
Discovery ,
Extrinsic Evidence ,
Generic Drugs ,
Incorporation by Reference ,
Injunctive Relief ,
Inter Partes Review (IPR) Proceeding ,
Jurisdiction ,
Patent Infringement ,
Patent Invalidity ,
Patent Terms ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Priority Patent Claims ,
Privity of Contract ,
Product of Nature Doctrine ,
Real Party in Interest ,
Scope of the Claim ,
Subsequent Litigation ,
Time-Barred Claims ,
Treatment Method Patents
Distribution Agreements Can Constitute Offers for Sale Under Section 102(b) -
In The Medicines Company v. Hospira, Inc., Appeal Nos. 2014-1469, 2014-1504, the Federal Circuit held that a distribution agreement qualified as...more
4/11/2018
/ Amended Complaints ,
Appeals ,
Broadest Reasonable Interpretation Standard ,
Claim Construction ,
Computer-Related Inventions ,
Direct Infringement ,
Federal Rule 12(b)(6) ,
Generic Drugs ,
Indefiniteness ,
Inter Partes Review (IPR) Proceeding ,
Motion to Dismiss ,
Obviousness ,
On-Sale Bar ,
Patent Invalidity ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Pleading Standards ,
Prior Art ,
Question of Fact ,
Question of Law ,
Remand ,
Reversal ,
Sales & Distribution Agreements ,
Section 101 ,
Standard of Review ,
Summary Judgment
“Common Sense” Alone Is Not a Sufficient Motivation to Combine References -
In In Re: Van Os, Appeal No. 2015-1975, the Federal Circuit held that the Patent Trial and Appeal Board’s reliance on intuition or common sense...more
3/9/2017
/ Appeals ,
Burden of Production ,
Divided Infringement ,
Inducements ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Infringement ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Prior Art ,
Product Labels ,
Remand ,
Standard of Review ,
Standing ,
Vacated
PTAB’s Final Written Decision in IPR Must Explain Its Basis for a Motivation to Combine References -
In In Re: Nuvasive, Inc., Appeal No. 2015-1670, the Federal Circuit vacated the PTAB’s obviousness finding in an IPR,...more
2/18/2017
/ Appeals ,
Claim Construction ,
Divided Infringement ,
Doctrine of Equivalents ,
Evidence ,
Induced Infringement ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Infringement ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Reversal
Expert Testimony Not Always Necessary to Establish Prima Facie Obviousness Case in Inter Partes Review -
In Belden Inc. v. Berk-Tek LLC, Appeal Nos. 2014-1575, 2014-1576, on appeal from an IPR, the Federal Circuit...more
12/28/2015
/ Appeals ,
Claim Construction ,
Expert Testimony ,
Incorporated by Reference ,
Inter Partes Review (IPR) Proceeding ,
International Litigation ,
International Trade Commission (ITC) ,
Jurisdiction ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Prior Art